arznei-telegramm 07/2019 contents

NEW ON THE MARKET
Dapagliflozin (FORXIGA): first oral antidiabetic for type 1 diabetes
Risankizumab (SKYRIZI) for psoriasis

THERAPY FROM A CRITICAL VIEWPOINT
COMPASS trial: pantoprazole safe, but without benefit

a-t READERS QUESTIONS AND COMMENTS
High dose statin for coronary heart disease?
Methotrexate (LANTAREL, generics) for rheumatoid arthritis or psoriasis … prefer subcutaneous over oral application?

IN BRIEF
Platelet aggregation inhibitors after cerebral haemorrhage – yes or no?

CURRENT ADR NETWORK REPORT
Generalized pruritus due to empagliflozin (JARDIANCE) free article

SIDE EFFECTS
Caution: increased mortality with the gout medication febuxostat (ADENURIC)
EMA: long-lasting sexual adverse effects due to SSRI and SNRI

e a-t ON THE INTERNET
Risankizumab (SKYRIZI) for psoriasis (long version)
Tocilizumab (ROACTEMRA): severe liver damage
EMA: long-lasting sexual adverse effects due to SSRI and SNRI (long version)